All News Annovis Bio, Inc.

Equities

ANVS

US03615A1088

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			5-day change	1st Jan Change
13.6 ^USD	+6.75%		+38.07%	-27.27%

Apr. 01	Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	CI
Mar. 29	Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 02	GL
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	Apr. 01	GL
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	Apr. 01	CI
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Top Midday Gainers	Mar. 20	MT
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Mar. 20	GL
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Mar. 20	AQ
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	Mar. 20	CI
Annovis Bio : Material Event - Form 8-K	Mar. 20	PU
Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding	Mar. 14	CI
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	Mar. 14	CI
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Annovis Bio Shares Fall After Downgrade From Brookline Capital	Feb. 28	MT
Brookline Capital Downgrades Annovis Bio to Hold From Buy, $9 Price Target	Feb. 28	MT
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	Feb. 27	GL
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	Feb. 27	AQ
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE	Feb. 15	AQ
Annovis Bio Completes Phase 2 Study of Alzheimer's Treatment Candidate	Feb. 14	MT
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease	Feb. 14	GL
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	Feb. 14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Annovis Bio, Inc.

Equities

ANVS

US03615A1088

All News

Filters